SCHEMBL983117

SCHEMBL983117

Cc1nc(I)c(C)n1-c1cc[nH]c(=O)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
DCTPP1 Q9H773 1/20 0.34
HCAR1 Q9BXC0 4/20 0.33
CYP1A2 P05177 2/20 0.33
TSHR P16473 2/20 0.33
CYP2C9 P11712 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KCNH2 Q12809 1/20 0.31
AOC3 Q16853 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981733 0.76 AOC3 (0.34) DCTPP1CYP1A2TSHRCYP2C9SMN1; SMN2
SCHEMBL12948765 0.74 XDH (0.41) DCTPP1TSHRCYP2C9ALDH1A1MAPT
SCHEMBL981741 0.73 HCAR1 (0.31) HCAR1SMN1; SMN2
SCHEMBL12948873 0.72 CYP1A2 (0.40) DCTPP1CYP1A2TSHRCYP2C9ALDH1A1
SCHEMBL12948830 0.72 GRM5 (0.37) PDE3BPDE3AKCNH2AOC3
SCHEMBL980911 0.71 GRM5 (0.41) TSHRALDH1A1HTTSMN1; SMN2KCNH2
SCHEMBL12948767 0.71 CYP1A2 (0.49) CYP1A2TSHRALDH1A1LMNAMAPT
SCHEMBL980914 0.70 PDE3B (0.37) PDE3BPDE3AALDH1A1LMNAMAPT
SCHEMBL6864903 0.69 GRM5 (0.42) TSHRALDH1A1LMNASMN1; SMN2HSD17B10
SCHEMBL981471 0.69 GRM5 (0.44) CYP1A2CYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102471309-B Imidazole derivatives as MGLUR5 antagonists HOFFMANN LA ROCHE 2014-09-03 CN disclosed
EP-2456765-B1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-05-01 EP disclosed
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
EP-2456765-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-05-30 EP disclosed
CN-102471309-A Imidazole derivatives as MGLUR5 antagonists HOFFMANN LA ROCHE 2012-05-23 CN disclosed
WO-2011006910-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 WO disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015202-A1 IMIDAZOLES GRM5, GRM1, GRIK5 PDE3B 998/4885PDE3A 776/4885DCTPP1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.